Cancer Res Treat.  2008 Sep;40(3):121-126.

Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity

• Lee HS
• Son CB
• Shin SH
• Kim YS

Abstract

PURPOSE
Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.
MATERIALS AND METHODS
Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.
RESULTS
Of the 86 participants (mean age, 48.5 years; range 20~65 years), cardiotoxicity developed in 21 pa-tients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.
CONCLUSIONS
The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.

Keyword

Hematologic neoplasms; Anthracycline; BNP; Cardiac toxicity

MeSH Terms

Arrhythmias, Cardiac
Brain
Chronic Disease
Echocardiography
Electrocardiography
Heart Failure
Hematologic Neoplasms
Humans
Leukemia
Lymphoma
Multiple Myeloma
Natriuretic Peptide, Brain
Prospective Studies
Troponin I
Natriuretic Peptide, Brain
Troponin I

Reference

1. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005; 23:7685–7696. PMID: 16234530.

2. Ewer M, Benjamin RS. Perry MC, editor. Cardiotoxicity of chemotherapeutic drugs. The chemotherapy sourcebook. 2001. 3rd ed. Philadelphia, PA: Lippincott: Williams & Wilkins;p. 458–468.

3. Bonneterre J, Roche H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol. 2004; 22:3070–3079. PMID: 15284257.

4. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003; 21:2349–2356. PMID: 12805337.

5. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004; 22:1864–1871. PMID: 15143078.

6. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med. 1978; 65:823–832. PMID: 707541.

7. Steinherz LJ, Yahalom J. DeVita VT, Hellman S, Rosenberg SA, editors. Cardiac toxicity. Cancer: principles and practice of oncology. 2001. 6th ed. Philadelphia, PA: Lippincott, Williams & Wilkins;p. 2904–2921.

8. Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol. 2003; 30:730–739. PMID: 14663774.

9. Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998; 16:545–550. PMID: 9469339.

10. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996; 53:461–470. PMID: 8960141.

11. Hale ER, Lipshultz S, Constine L. Latent injury after the double-edged sword of chemo/radiation. 2005 ASCO educational book. 2005. Alexandria, VA: American Society of Clinical Oncology;p. 739–746.

12. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91:710–717. PMID: 496103.

13. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995; 332:1738–1743. PMID: 7760889.

14. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141:367–374. PMID: 11231433.

15. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001; 37:4–9. PMID: 11466716.

16. Nousiainen T, Vanninen E, Jantunen E, Remes J, Ritanen E, Vuolteenaho O, et al. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin Sci (Lond). 2001; 101:601–607. PMID: 11724646.

17. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol. 1999; 62:135–141. PMID: 10052718.

18. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005; 23:7820–7826. PMID: 16258084.

19. Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol. 2004; 22:769–773. PMID: 14990630.

20. Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu ZX, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998; 58:195–197. PMID: 9443390.

21. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000; 36:517–522. PMID: 10933366.

22. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001; 19:1444–1454. PMID: 11230490.

23. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988; 319:745–752. PMID: 3137469.

24. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997; 15:1333–1340. PMID: 9193324.

25. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285:1441–1446. PMID: 5122894.